Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Trans Tasman Radiation Oncology Group
- Target Recruit Count
- 35
- Registration Number
- NCT05796089
- Locations
- 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
- Conditions
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT05771480
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 56
- Registration Number
- NCT05757843
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
- Conditions
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05720260
- Locations
- 🇨🇳
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 44
- Registration Number
- NCT05718297
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷Caen - CHU, Caen, France
🇫🇷Hôpital de Marseille, Marseille, France
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-11-27
- Target Recruit Count
- 32
- Registration Number
- NCT05713838
- Locations
- 🇩🇪
Charite Univeristätsmedizin Berlin, Berlin, Germany
🇩🇪Krankenhaus St. Joseph-Stift GmbH, Bremen, Germany
🇩🇪Klinikum Darmstadt GmbH, Darmstadt, Germany
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05712356
- Locations
- 🇪🇸
Hospital Universitario de Vinalopó, Elche, Alicante, Spain
🇪🇸Hospital Universitario de Jerez, Jerez De La Frontera, Cadiz, Spain
🇪🇸Start Madrid - Hospital Universitario HM Sanchinarro, Madrid, Spain
SIRT With Tremelimumab and Durvalumab for Resectable HCC
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Jiping Wang, MD, PhD
- Target Recruit Count
- 20
- Registration Number
- NCT05701488
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 28
- Registration Number
- NCT05696782
- Locations
- 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1350
- Registration Number
- NCT05687266
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.